N@N

Joseph Schwartz Maintained (BMRN) at Buy with Increased Target to $130 on, Feb 3rd, 2023

Joseph Schwartz of SVB Leerink, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $122 to $130 on, Feb 3rd, 2023.

Joseph has made no other calls on BMRN in the last 4 months.

There are 9 other peers that have a rating on BMRN. Out of the 9 peers that are also analyzing BMRN, 4 agree with Joseph's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Kostas Biliouris of "BMO Capital" Initiated at Hold and Held Target at $107 on, Monday, January 30th, 2023
• Whitney Ijem of "Canaccord Genuity" Initiated at Hold and Held Target at $119 on, Wednesday, January 18th, 2023
• Andreas Argyrides of "Wedbush" Maintained at Hold with Increased Target to $83 on, Wednesday, January 11th, 2023
• Luca Issi of "RBC Capital" Maintained at Hold with Increased Target to $95 on, Thursday, October 13th, 2022

These are the ratings of the 5 analyists that currently disagree with Joseph

---

• Matthew Harrison of "Morgan Stanley" Maintained at Buy with Increased Target to $132 on, Tuesday, January 24th, 2023
• Akash Tewari of "Jefferies" Maintained at Strong Buy with Increased Target to $120 on, Tuesday, November 29th, 2022
• Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Increased Target to $110 on, Monday, October 31st, 2022
• Tiago Fauth of "Credit Suisse" Maintained at Buy with Decreased Target to $110 on, Thursday, October 27th, 2022
• Jessica Fye of "JP Morgan" Maintained at Buy with Decreased Target to $112 on, Monday, October 24th, 2022

Contributing Sources

---